Stockscreener 앱 받기
177.73
2.52%
-4.59
전일 마감가:
$182.32
열려 있는:
$181.66
하루 거래량:
115.43K
Relative Volume:
0.49
시가총액:
$3.48B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
70.81
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
-1.80%
1개월 성능:
+7.09%
6개월 성능:
+75.47%
1년 성능:
+77.16%
1일 변동 폭
$177.35
$182.12
1주일 범위
$177.35
$186.40
52주 변동 폭
$93.58
$186.40
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
177.73 | 3.55B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Stifel | Buy |
| 2024-10-03 | 개시 | Oppenheimer | Outperform |
| 2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 재개 | Stephens | Overweight |
| 2021-02-04 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-06 | 개시 | Barclays | Overweight |
| 2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
| 2020-03-10 | 개시 | Guggenheim | Neutral |
| 2020-02-06 | 개시 | The Benchmark Company | Buy |
| 2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-03 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-06 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-11 | 재확인 | Argus | Buy |
| 2018-08-17 | 개시 | Goldman | Neutral |
| 2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 개시 | Argus | Buy |
| 2017-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-05 | 재개 | H.C. Wainwright | Buy |
| 2016-10-05 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 개시 | Sidoti | Buy |
| 2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
Is Ligand Pharmaceuticals Incorporated forming a reversal patternWatch List & Daily Stock Trend Watchlist - newser.com
Trend analysis for Ligand Pharmaceuticals Incorporated this weekWeekly Trading Summary & AI Enhanced Trading Signals - newser.com
Published on: 2025-10-12 10:25:04 - newser.com
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution - simplywall.st
Villere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Order flow analysis tools used on Ligand Pharmaceuticals IncorporatedPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
How FDA Approval of Lasix ONYU Expands Ligand Pharmaceuticals' (LGND) Royalty Pipeline and Revenue Potential - simplywall.st
Ligand Pharmaceuticals Hits New 52-Week High of $186.40 - Markets Mojo
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients - MarketScreener
Ligand (LGND) Gains FDA Approval for Lasix ONYU, Enhancing Heart Failure Treatment - GuruFocus
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients - Quiver Quantitative
Ligand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients - GlobeNewswire Inc.
Is Ligand Pharmaceuticals Incorporated (LGDN) stock bottoming after sell off2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Risk adjusted return profile for Ligand Pharmaceuticals Incorporated analyzedGlobal Markets & Short-Term High Return Ideas - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $184.26 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $183.81 - Markets Mojo
What analysts say about Ligand Pharmaceuticals Incorporated LGDN stockStock Rotation Strategies & Access Insider-Level Stock Analysis - earlytimes.in
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $183.98 By Investing.com - Investing.com Canada
Hot Picks: Three mid-cap stock picks poised for growth amid strong sector tailwinds - BNN Bloomberg
How to read the order book for Ligand Pharmaceuticals IncorporatedEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $181.62 - Markets Mojo
Press Release: Ligand Reports First Quarter 2025 Financial Results - 富途牛牛
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals Hits New 52-Week High at $177.77 - Markets Mojo
Can Ligand Pharmaceuticals Incorporated stock deliver sustainable ROE2025 Technical Overview & Real-Time Buy Signal Alerts - newser.com
Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Price Target Increased by 410.53% to 0.05 - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $172.49 By Investing.com - Investing.com Canada
What drives Ligand Pharmaceuticals Incorporated LGDN stock priceBollinger Bands Signals & Affordable Stock Market Tips - earlytimes.in
What drives Ligand Pharmaceuticals Incorporated stock priceHead and Shoulders Patterns & Small Budget Capital Gains - Early Times
Ligand Pharmaceuticals Hits New 52-Week High of $170.78 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $172.45 - Markets Mojo
Congress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares By Investing.com - Investing.com Australia
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor - GuruFocus
Arecor Therapeutics announces royalty financing agreement with Ligand to raise up to $11 mln - MarketScreener
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month HighTime to Buy? - MarketBeat
Contravisory Investment Management Inc. Acquires New Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Analysts Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $176.50 - MarketBeat
Strs Ohio Takes Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
What earnings revisions data tells us about Ligand Pharmaceuticals IncorporatedJuly 2025 Big Picture & Smart Swing Trading Alerts - newser.com
Jobs Data: What is the dividend yield of Ligand Pharmaceuticals IncorporatedQuarterly Portfolio Report & Smart Allocation Stock Tips - khodrobank.com
Is now a turning point for Ligand Pharmaceuticals IncorporatedTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
Will Ligand Pharmaceuticals Incorporated rebound enough to break even2025 AllTime Highs & Daily Chart Pattern Signals - newser.com
Aug Setups: Is Ligand Pharmaceuticals Incorporated in a long term uptrendMarket Performance Summary & Capital Efficient Trading Techniques - خودرو بانک
Rate Cut: Can Ligand Pharmaceuticals Incorporated outperform in the next rallyWatch List & Advanced Swing Trade Entry Alerts - خودرو بانک
Earnings visualization tools for Ligand Pharmaceuticals Incorporated2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):